We are analyzing https://link.springer.com/article/10.1007/s10555-021-09968-0.

Title:
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer | Cancer and Metastasis Reviews
Description:
Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or antitumor effect. Tumor-infiltrating CD8+ T cells and natural killer (NK) cells perform as effector cells against tumor cells and are associated with better clinical outcome. Immunotherapy approaches that improve the antitumor activity and proliferation of CD8+ T and NK cells include PD-1/PD-L1 blockade, CAR T cell therapy, or ex vivo-stimulated NK cells. A subset of CD8+ T cells, tissue-resident memory T cells, has also recently been associated with good prognosis in breast cancer patients, and has potential to serve as a predictive biomarker and therapeutic target. Tumor-infiltrating B cells also secrete apoptosis-inducing IgG antibodies and can act as antigen-presenting cells to prime CD4+ and CD8+ T cells. On the other hand, regulatory T and regulatory B cells modulate the immune response from CD8+ T cells and NK cells by secreting immunosuppressive cytokines and inhibiting maturation of antigen-presenting cells (APCs). These regulatory cells are typically associated with poor prognosis, therefore rendering suppression of their regulatory function a key immunotherapeutic strategy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

pubmed, article, google, scholar, cancer, cas, cells, breast, central, cell, patients, regulatory, journal, research, httpsdoiorgs, tumor, immunol, lymphocytes, clinical, tumorinfiltrating, immunology, natural, oncology, immune, memory, nature, human, killer, prognostic, response, phase, res, expression, wang, interleukin, study, metastatic, triplenegative, dendritic, med, lee, prognosis, immunotherapy, therapy, immunity, treatment, function, chemotherapy, httpsdoiorgjimmunol, antigen,

Topics {✒️}

fda%20grants%20accelerated%20approval%20to%20pembrolizumab%20for%20locally%20recurrent databases/fda-grants-accelerated-approval-pembrolizumab-locally-recurrent-unresectable metastatic%20triple%20negative%20breast%20cancer&text= p53-peptide-pulsed dendritic cells anti–pd-1/pd-l1 therapy anti-pd-l1 antibody avelumab month download article/chapter pd-l1 + tumor-infiltrating lymphocytes her2/neu-expressing malignancies t-cell metagene predicts tumors express pd-l1 anti-pd-l1 therapy anti-pd-l1 antibody triple-negative breast cancers her2-positive breast cancers tumor-induced composite subsets text=approvals%20and%20databases tumor-specific tissue-resident memory chimeric antigen receptor-modified anti-cd3/cd28 promotes triple-negative breast cancer natural killer-mediated cytotoxicity node-negative breast cancer pd-l1 expression correlates tumor-draining lymph nodes %20november%2013%2c%202020%2c%20the keytruda%2c%20merck%20%26%20co h-2-deficient lymphoma variants pd-l1-blockade resistance cd8+cd103+ tumor-infiltrating lymphocytes cd8+ t-cell infiltration locally recurrent unresectable versus single-agent chemotherapy 2/neu protein-specific antibody human nk-cell cytokine gov/drugs/drug-approvals β-d-mannuronic acid writing—original draft preparation breast cancer—adverse events phospholipase cgamma-dependent pathway tumor-infiltrating lymphocyte aggregates forkhead/winged-helix protein double-negative breast cancer tumor-infiltrating human cd4 her2-specific therapeutic antibodies early-stage breast cancer regulatory t-cell function human tissue-resident memory long-lived plasma cell synergistically increase il-10-producing

Questions {❓}

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer
         description:Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or antitumor effect. Tumor-infiltrating CD8+ T cells and natural killer (NK) cells perform as effector cells against tumor cells and are associated with better clinical outcome. Immunotherapy approaches that improve the antitumor activity and proliferation of CD8+ T and NK cells include PD-1/PD-L1 blockade, CAR T cell therapy, or ex vivo-stimulated NK cells. A subset of CD8+ T cells, tissue-resident memory T cells, has also recently been associated with good prognosis in breast cancer patients, and has potential to serve as a predictive biomarker and therapeutic target. Tumor-infiltrating B cells also secrete apoptosis-inducing IgG antibodies and can act as antigen-presenting cells to prime CD4+ and CD8+ T cells. On the other hand, regulatory T and regulatory B cells modulate the immune response from CD8+ T cells and NK cells by secreting immunosuppressive cytokines and inhibiting maturation of antigen-presenting cells (APCs). These regulatory cells are typically associated with poor prognosis, therefore rendering suppression of their regulatory function a key immunotherapeutic strategy.
         datePublished:2021-05-07T00:00:00Z
         dateModified:2021-05-07T00:00:00Z
         pageStart:519
         pageEnd:536
         sameAs:https://doi.org/10.1007/s10555-021-09968-0
         keywords:
            Breast cancer
            Immunotherapy
            Tumor microenvironment
            TILs
            T cells
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-021-09968-0/MediaObjects/10555_2021_9968_Fig1_HTML.png
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:40
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Molly A. Nelson
               affiliation:
                     name:PDX Pharmaceuticals, Inc.
                     address:
                        name:PDX Pharmaceuticals, Inc., Portland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Worapol Ngamcherdtrakul
               affiliation:
                     name:PDX Pharmaceuticals, Inc.
                     address:
                        name:PDX Pharmaceuticals, Inc., Portland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shiuh-Wen Luoh
               affiliation:
                     name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University
                     address:
                        name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Wassana Yantasee
               url:http://orcid.org/0000-0002-0989-363X
               affiliation:
                     name:PDX Pharmaceuticals, Inc.
                     address:
                        name:PDX Pharmaceuticals, Inc., Portland, USA
                        type:PostalAddress
                     type:Organization
                     name:Oregon Health and Science University
                     address:
                        name:Department of Biomedical Engineering, Oregon Health and Science University, Portland, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer
      description:Increased levels of total tumor-infiltrating lymphocytes (TILs) are generally associated with good prognosis in several breast cancer subtypes. Subtypes of TILs impact both tumor cells and immune cells in a variety of different ways, leading to either a pro-tumor or antitumor effect. Tumor-infiltrating CD8+ T cells and natural killer (NK) cells perform as effector cells against tumor cells and are associated with better clinical outcome. Immunotherapy approaches that improve the antitumor activity and proliferation of CD8+ T and NK cells include PD-1/PD-L1 blockade, CAR T cell therapy, or ex vivo-stimulated NK cells. A subset of CD8+ T cells, tissue-resident memory T cells, has also recently been associated with good prognosis in breast cancer patients, and has potential to serve as a predictive biomarker and therapeutic target. Tumor-infiltrating B cells also secrete apoptosis-inducing IgG antibodies and can act as antigen-presenting cells to prime CD4+ and CD8+ T cells. On the other hand, regulatory T and regulatory B cells modulate the immune response from CD8+ T cells and NK cells by secreting immunosuppressive cytokines and inhibiting maturation of antigen-presenting cells (APCs). These regulatory cells are typically associated with poor prognosis, therefore rendering suppression of their regulatory function a key immunotherapeutic strategy.
      datePublished:2021-05-07T00:00:00Z
      dateModified:2021-05-07T00:00:00Z
      pageStart:519
      pageEnd:536
      sameAs:https://doi.org/10.1007/s10555-021-09968-0
      keywords:
         Breast cancer
         Immunotherapy
         Tumor microenvironment
         TILs
         T cells
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-021-09968-0/MediaObjects/10555_2021_9968_Fig1_HTML.png
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:40
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Molly A. Nelson
            affiliation:
                  name:PDX Pharmaceuticals, Inc.
                  address:
                     name:PDX Pharmaceuticals, Inc., Portland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Worapol Ngamcherdtrakul
            affiliation:
                  name:PDX Pharmaceuticals, Inc.
                  address:
                     name:PDX Pharmaceuticals, Inc., Portland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shiuh-Wen Luoh
            affiliation:
                  name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University
                  address:
                     name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Wassana Yantasee
            url:http://orcid.org/0000-0002-0989-363X
            affiliation:
                  name:PDX Pharmaceuticals, Inc.
                  address:
                     name:PDX Pharmaceuticals, Inc., Portland, USA
                     type:PostalAddress
                  type:Organization
                  name:Oregon Health and Science University
                  address:
                     name:Department of Biomedical Engineering, Oregon Health and Science University, Portland, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:40
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:PDX Pharmaceuticals, Inc.
      address:
         name:PDX Pharmaceuticals, Inc., Portland, USA
         type:PostalAddress
      name:PDX Pharmaceuticals, Inc.
      address:
         name:PDX Pharmaceuticals, Inc., Portland, USA
         type:PostalAddress
      name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University
      address:
         name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, USA
         type:PostalAddress
      name:PDX Pharmaceuticals, Inc.
      address:
         name:PDX Pharmaceuticals, Inc., Portland, USA
         type:PostalAddress
      name:Oregon Health and Science University
      address:
         name:Department of Biomedical Engineering, Oregon Health and Science University, Portland, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Molly A. Nelson
      affiliation:
            name:PDX Pharmaceuticals, Inc.
            address:
               name:PDX Pharmaceuticals, Inc., Portland, USA
               type:PostalAddress
            type:Organization
      name:Worapol Ngamcherdtrakul
      affiliation:
            name:PDX Pharmaceuticals, Inc.
            address:
               name:PDX Pharmaceuticals, Inc., Portland, USA
               type:PostalAddress
            type:Organization
      name:Shiuh-Wen Luoh
      affiliation:
            name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University
            address:
               name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, USA
               type:PostalAddress
            type:Organization
      name:Wassana Yantasee
      url:http://orcid.org/0000-0002-0989-363X
      affiliation:
            name:PDX Pharmaceuticals, Inc.
            address:
               name:PDX Pharmaceuticals, Inc., Portland, USA
               type:PostalAddress
            type:Organization
            name:Oregon Health and Science University
            address:
               name:Department of Biomedical Engineering, Oregon Health and Science University, Portland, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:PDX Pharmaceuticals, Inc., Portland, USA
      name:PDX Pharmaceuticals, Inc., Portland, USA
      name:VA Portland Health Care System, Knight Cancer Institute, Oregon Health and Science University, Portland, USA
      name:PDX Pharmaceuticals, Inc., Portland, USA
      name:Department of Biomedical Engineering, Oregon Health and Science University, Portland, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(814)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.41s.

LINK . SPRINGER . COM {}